Why the study?
Advances in recognition and treatment of right heart clot-in-transit have led to endovascular therapies increasingly becoming preferred due to rapid debulking and lower morbidity, mitigating concomitant thrombolytics.
Endovascular aspiration thrombectomy offers a promising, minimally invasive alternative to traditional anticoagulation, thrombolysis, or surgical embolectomy for the high-mortality condition of right heart thrombus.
Large-bore aspiration may be feasible for clot-in-transit; leaves open need for comparative trials before practice change.
Right heart thrombus is a challenging high mortality disease typically seen in the setting of pulmonary embolism. Traditional treatments have included anticoagulation, thrombolysis, and surgical embolectomy. Advances in recognition and treatment of clot-in-transit have led to the development of endovascular therapies increasingly becoming the preferred method of treatment due to rapid debulking and lower morbidity. Novel endovascular devices are large bore aspiration thrombectomy systems which mitigate the use of concomitant thrombolytics. The article reviews the disease process, relevant literature, and current endovascular devices and strategies for the treatment of right heart thrombus and clot-in-transit.
No takes yet. Share an insight, caveat, or question.
Mathevosian et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: